This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
BD (BDX) Q3 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.
Avanos (AVNS) Q2 Earnings Top Estimates, Gross Margin Contracts
by Zacks Equity Research
Strength in Avanos' (AVNS) Digestive Health segment drives its second-quarter performance.
QuidelOrtho (QDEL) Q2 Earnings Beat Estimates, U.S. Sales Down
by Zacks Equity Research
QuidelOrtho's (QDEL) second-quarter results reflect growth in revenues. However, gross profit continues to decline.
Medtronic Stock Moves Above 50-Day SMA: Should You Buy MDT?
by Urmimala Biswas
Medtronic's (MDT) stock finally breaking above its 50-day SMA can be a piece of good news for investors, signaling an uptrend.
Are Options Traders Betting on a Big Move in Boston Scientific (BSX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Boston Scientific (BSX) stock based on the movements in the options market lately.
Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales
by Zacks Equity Research
Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.
Cencora (COR) Q3 Earnings Beat Estimates, '24 View Raised
by Zacks Equity Research
Cencora's (COR) third-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.
Boston Scientific (BSX) Rides on Global Growth, Buyouts
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
GE HealthCare (GEHC) Q2 Earnings Beat Estimates, Net Margin Up
by Zacks Equity Research
GE HealthCare's (GEHC) second-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.
DENTSPLY SIRONA (XRAY) Q2 Earnings Miss, Revenues Decline Y/Y
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2024 results showcase a year-over-year decline in earnings as well as sales.
Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company???s transformational plans continue to benefit its operating income.
Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its second-quarter sales amid business challenges.
Revvity (RVTY) Q2 Earnings Beat Estimates, Guidance Revised
by Zacks Equity Research
Revvity's (RVTY) second-quarter results showcase a decline in life sciences segmental revenues.
Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.
3 Reasons Why You Should Hold HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
Alphatec's (ATEC) New EOS Insight System to Boost Spine Care
by Zacks Equity Research
Alphatec (ATEC) announces the commercial launch of its EOS Insight, an end-to-end spine surgery platform powered by standardized EOSedge scans and artificial intelligence.
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
Boston Scientific (BSX) Q2 Earnings Beat, Organic Sales Rise
by Zacks Equity Research
Boston Scientific (BSX) registers a strong year-over-year improvement in sales, indicating solid market share gains in legacy businesses across all geographic regions.
Veeva Systems' (VEEV) Vault EDC to Boost Vita Global's Workflow
by Zacks Equity Research
Veeva Systems' (VEEV) Vault EDC is likely to aid the CRO in delivering a better experience to patients, research sites and sponsors.
PacBio's (PACB) Revio System to Boost Novogene's German Lab
by Zacks Equity Research
PacBio (PACB) announces that Novogene is set to use PACB's Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany.
Boston Scientific (BSX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
by Zacks Equity Research
Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.